Literature DB >> 336256

Metabolism of l-bunolol.

F J Di Carlo, F J Leinweber, J M Szpiech, I W Davidson.   

Abstract

The metabolism of l-bunolol, a new beta-blocking drug, was studied in man after single oral 3-mg doses of 3H-labeled compound. Absorption from the gut was rapid and virtually complete. Peak levels of bunolol and of dihydrobunolol, an active metabolite, were observed at 1 hr. Excretion of the administered radioactivity was mainly into the urine (78% in 4 days), with only 3% appearing in the feces. Bunolol, bunolol glucuronide, bunolol sulfate, dihydrobunolol, and dihydrobunolol glucuronide were identified and quantified in the plasma. These compounds represented 82% of the radioactivity in plasma at 30 min and 55% at 24 hr. Plasma half-lives (+/-S.D.) were estimated to be 6.1 +/- 0.3 hr for bunolol, 9.1 +/- 1.9 hr for bunolol glucuronide, 17.4 +/- 2.5 hr for bunolol sulfate, 7.1 +/- 0.5 hr for dihydrobunolol, and 7.7 +/- 0.8 hr for dihydrobunolol glucuronide.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 336256     DOI: 10.1002/cpt1977226858

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

Review 1.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

Review 2.  Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; S P Clissold
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.